George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 8.00
Ask: 10.00
Change: -1.00 (-10.00%)
Spread: 2.00 (25.00%)
Open: 9.00
High: 9.00
Low: 8.25
Prev. Close: 10.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Redx Pharma Plc

15 Jan 2020 15:17

RNS Number : 9329Z
Sarah Hooker
15 January 2020
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Sarah Hooker

Dennis Hallahane

Paulene Hallahane

Bridget Hallahane

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

14 January 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

1p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

2,225,100

1.76

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

2,225,100

1.76

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

15 January 2020

Contact name:

Sarah Hooker

Telephone number*:

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RETGPURUGUPUGAA
Date   Source Headline
19th Nov 20187:00 amRNSCFO Announcement
19th Nov 20187:00 amRNSPreliminary Results for year ended 30 Sept 2018
14th Nov 20187:00 amRNSRedx announces new drug development candidate
9th Nov 20189:51 amEQSHardman & Co Research: Redx Pharma (REDX):ROCK2 inhibitors in chronic kidney disease
5th Nov 20187:00 amRNSPreclinical data presented at cancer conference
31st Oct 20187:00 amRNSNotice of Results
29th Oct 20187:00 amRNSRedx notes election of Lisa Anson to UK BIA BOD
26th Oct 20187:00 amRNSDetails from Redx ROCK2 inhibitor poster
22nd Oct 20187:00 amRNSRedx ROCK2 inhibitors poster to be presented
2nd Oct 20181:40 pmEQSHardman & Co Research: Redx Pharma (REX): Strategy launch
6th Sep 20187:15 amEQSHardman & Co Research: Redx Pharma (REDX): Back to the clinic
4th Sep 20187:00 amRNSRedx Pharma Announces Way Forward For RXC004
18th Jun 20187:15 amEQSHardman & Co Research: Redx Pharma (REDX): 'Focus, Realism and Results' - Ian Ross, Chairman
4th Jun 20187:00 amRNSDirectorate Update and Grant of Options
30th May 20187:00 amRNSInterim Results
15th May 201812:00 pmEQSHardman & Co Research: Redx Pharma (REDX): Clinical and corporate update
25th Apr 201810:57 amRNSShare Purchase by Chairman
25th Apr 20189:05 amRNSSecond Price Monitoring Extn
25th Apr 20189:00 amRNSPrice Monitoring Extension
24th Apr 20187:00 amRNSRedx Appoints Senior AstraZeneca Executive as CEO
13th Apr 20188:19 amRNSHolding(s) in Company
12th Apr 201811:28 amRNSHolding(s) in Company
29th Mar 20187:00 amRNSRXC004 Clinical Trial Update
22nd Mar 20187:00 amRNSRedx and Deinove sign option and licence agreement
15th Mar 20187:00 amRNSPoster Presentation at AACR Annual Meeting
6th Mar 20184:33 pmRNSResult of AGM
12th Feb 201810:23 amRNSPosting of Annual Accounts & AGM notice
6th Feb 20187:00 amRNSFirst Patient Dosed in Phase 1/2a Trial of RXC004
22nd Jan 20187:00 amRNSAppointment of Chief Medical Officer
28th Dec 201711:28 amRNSHolding(s) in Company
27th Dec 20175:45 pmRNSShare Purchase by Directors
22nd Dec 20177:00 amRNSGrant of Options
20th Dec 20177:00 amRNSFinal Results for the Year Ended 30 September 2017
14th Dec 20173:56 pmRNSHolding(s) in Company
8th Dec 20175:04 pmRNSHolding(s) in Company
14th Nov 201711:30 amRNSDirector/PDMR Shareholding
13th Nov 20177:15 amRNSHardman Research: Streamlined and clean
6th Nov 201712:00 pmRNSRestoration - Restoration Redx Pharma plc
6th Nov 20177:00 amRNSRedx updates strategy and resumes shares trading
27th Oct 20178:00 amRNSUpdate on Application to the High Court
13th Oct 20177:00 amRNSUpdate on Court Process
31st Aug 20179:00 amRNSRedx to present new scientific data at ESMO 2017
24th Aug 20179:42 amRNSDistribution to Unsecured Creditors
14th Aug 201710:05 amRNSDirectorate Change
10th Aug 20178:00 amRNSPublication of Joint Administrators' Proposals
31st Jul 20177:00 amRNSDisposal of BTK inhibitor drug development program
23rd Jun 20172:38 pmRNSMHRA approval of Clinical Trial Application
22nd Jun 20177:00 amRNSUpdate on Suspension of Trading
24th May 20176:35 pmRNSStatement re. Suspension
24th May 20174:35 pmRNSSuspension - Redx Pharma plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.